Rafael Bejar M.D., Ph.D.
Net Worth
Last updated:
What is Rafael Bejar M.D., Ph.D. net worth?
The estimated net worth of Dr. Rafael Bejar M.D., Ph.D. is at least $2,288,709 as of 19 Nov 2021. He owns shares worth $21,029 as insider and has received compensation worth at least $2,267,680 in Aptose Biosciences Inc..
What is the salary of Rafael Bejar M.D., Ph.D.?
Dr. Rafael Bejar M.D., Ph.D. salary is $566,920 per year as Senior Vice President & Chief Medical Officer in Aptose Biosciences Inc..
How old is Rafael Bejar M.D., Ph.D.?
Dr. Rafael Bejar M.D., Ph.D. is 53 years old, born in 1972.
What stocks does Rafael Bejar M.D., Ph.D. currently own?
As insider, Dr. Rafael Bejar M.D., Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Aptose Biosciences Inc. (APTO) | Senior Vice President & Chief Medical Officer | 10,000 | $2.1 | $21,029 |
What does Aptose Biosciences Inc. do?
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
